Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/25/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
5/22/2023 | $31.00 | Buy | CL King |
2/24/2022 | $47.00 → $41.00 | Overweight | Keybanc |
1/7/2022 | $37.00 → $36.00 | Underweight | Morgan Stanley |
8/4/2021 | $45.00 → $41.00 | Underweight | Morgan Stanley |
8/4/2021 | $60.00 → $45.00 | Overweight → Equal-Weight | Stephens |
8/4/2021 | $55.00 → $47.00 | Overweight | Keybanc |
JMP Securities analyst Daniel Stauder reiterates Avanos Medical (NYSE:AVNS) with a Market Perform.
Avanos Medical (NYSE:AVNS) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.21 by 9.52 percent. This is a 29.63 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $166.100 million which beat the analyst consensus estimate of $162.900 million by 1.96 percent. This is a 4.27 percent increase over sales of $159.300 million the same period last year.
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
ALPHARETTA, Ga., Nov. 12, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in an analyst-led fireside chat at the Stifel 2024 Healthcare Conference at the Lotte New York Palace in New York on Tuesday, Nov. 19 at approximately 3:35 p.m. ET. A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site. About Avanos Medical, Inc. Avanos Medical, Inc. (NYSE:AVNS) is a medical technology company focused o
ALPHARETTA, Ga., Nov. 11, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) announced today that the Centers for Medicare and Medicaid Services (CMS) has issued its final Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025. This rule, effective Jan. 1, 2025, implements the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act that mandates separate Medicare payment for qualifying non-opioid drugs and devices. The NOPAIN Act, passed as part of the Consolidated Appropriation Act of 2023,
ALPHARETTA, Ga., Nov. 8, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in a fireside chat at the UBS 2024 Healthcare Conference on Tues., Nov. 12 at approximately 2:45 p.m. Pacific Time. A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site. About Avanos Medical, Inc. Avanos Medical, Inc. (NYSE:AVNS) is a medical technology company focused on delivering clinically superior medical device so
8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)
10-Q - AVANOS MEDICAL, INC. (0001606498) (Filer)
8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)
SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)
3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)
KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight
CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00
Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously
ALPHARETTA, Ga., Oct. 30, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody. Gary Blackford, Avanos Board Chairman, noted, "Joe has decided to retire after leading Avanos for the past seven years. Joe has agreed to assist the Company in the transition of leadership, and will continue to consult with the Company through April of next year. Avanos is better positioned financially and organizationally today to achieve its longer-term value creation goals because of Joe's lea
ALPHARETTA, Ga., Oct. 23, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2024 on Wednesday, Oct. 30 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer. To join the live conference call, dial 1-800-836-8184 in the United States. A
ALPHARETTA, Ga., July 31, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported second quarter 2024 financial results. "We are pleased with our second quarter results and the cumulative progress we have made at the mid-year point," said Joe Woody, Avanos's chief executive officer. Woody continued, "Digestive Health continues to lead in delivering high-single digit growth while Pain Management and Recovery performance is improving with quarter-over-quarter sequential growth, and we are seeing meaningful progress on our other transformation objectives, all of whic
ALPHARETTA, Ga., July 1, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors. "We are excited to welcome Indrani Franchini to the Avanos board," remarked Gary Blackford, Avanos board chair. "Her experience with a broad range of global companies will be invaluable to Avanos as we pursue our vision of getting patients back to the things that matter." "Avanos is committed to addressing some of today's most important healthcare needs and I am thrilled to join it
ALPHARETTA, Ga., May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain. In this role, Delgado will lead the teams focused on implementing continuous improvements within the Company's end-to-end supply chain capabilities worldwide. Delgado joins Avanos from Jabil Healthcare, the industry's largest global provider of healthcare manufacturing solutions, where he most recently served as vice president of its global medical technology business. His background includ
ALPHARETTA, Ga., March 6, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Dr. Lisa Egbuonu-Davis, currently vice president, medical innovations, for DH Diagnostics, LLC, an affiliate of Danaher Corporation, has been appointed as a new independent member of the Avanos board of directors and will serve as a member of the compliance and governance committees. "We are pleased and excited to welcome Lisa Egbuonu-Davis to the Avanos board," commented Gary Blackford, Avanos board chair. "Her deep strategic and operational expertise in the healthcare sector